N. Dohollou

发表

Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.

O. Trédan, F. Gernier, A. Gompel, 2021, Gynecologic oncology.

Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.

L. Mauriac, J. Canon, G. Romieu, 2009 .

Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

I. Ray-Coquard, A. Floquet, D. Berton‐Rigaud, 2019, Journal of Clinical Oncology.

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.

P. Fasching, F. Marmé, I. Vergote, 2022, European journal of cancer.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer

J. Robert, N. Dohollou, F. Dalenc, 2020, Clinical pharmacology and therapeutics.

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group

B. Weber, I. Ray-Coquard, N. Dohollou, 2009, British Journal of Cancer.

Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.

X. Pivot, N. Dohollou, J. Gligorov, 2011, European journal of cancer.

UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.

J. Lemonnier, M. Campone, J. Canon, 2019, European journal of cancer.

Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients.

J. Blay, A. Cesne, A. Le Cesne, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New advances in DPYD genotype and risk of severe toxicity under capecitabine

F. Pinguet, C. Béroud, A. V. van Kuilenburg, 2017, PloS one.

Maintaining professional activity during breast cancer treatment.

N. Dohollou, H. Naman, A. Lortholary, 2016, European journal of cancer care.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

I. Bièche, F. Clatot, F. André, 2022, Cancer Research.

A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.

C. Genestie, D. Berton, V. Serra, 2023, Gynecologic oncology.

1198 Treatment of localized Ewing's sarcoma in young adults. A study of the French society of pediatric oncology

J. Zucker, N. Dohollou, O. Oberlin, 1995 .

1200 Adults with Ewing's sarcoma: A retrospective study of 146 cases

A. Cesne, T. Tursz, N. Dohollou, 1995 .

Serum neuron-specific enolase (NSE) as a tumour marker for the Ewing's sarcoma family of tumours.

A. Le Cesne, T. le Chevalier, N. Dohollou, 1996, European journal of cancer.

Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.

D. Berton, I. Ray-Coquard, A. Floquet, 2023, Gynecologic oncology.

Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer

J. Vansteenkiste, P. Zatloukal, N. Dohollou, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial

F. Marmé, K. Yonemori, I. Vergote, 2020 .

[Node negative breast cancer. Beyond international consensus: a pragmatic approach].

T. Delozier, M. Namer, F. Penault-Llorca, 2011, Bulletin du cancer.

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

O. Trédan, F. Gernier, E. Kalbacher, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.

J. Blay, A. Italiano, N. Sevenet, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P1-18-28: Phase IV study evaluating effectiveness and safety of talazoparib in patients with locally advanced or metastatic HER2 negative breast cancer and a BRCA1 or BRCA2 mutation (ViTAL)

P. Pujol, N. Dohollou, Jean-David Fumet, 2022, Cancer Research.

Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program

F. Bidard, N. Dohollou, S. Ladoire, 2023, Scientific reports.

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

J. Lemonnier, J. Pierga, P. Viens, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research

C. Genestie, S. Dedieu, N. Dohollou, 2024, Molecular cancer.